KR20130130022A - 5-클로로-ｎ2-(2-이소프로폭시-5-메틸-4-피페리딘-4-일-페닐)-ｎ4[2-(프로판-2-술포닐)-페닐]-피리미딘-2,4-디아민의 결정질 형태 - Google Patents

5-클로로-ｎ2-(2-이소프로폭시-5-메틸-4-피페리딘-4-일-페닐)-ｎ4[2-(프로판-2-술포닐)-페닐]-피리미딘-2,4-디아민의 결정질 형태 Download PDF

Info

Publication number
KR20130130022A
KR20130130022A KR1020137018605A KR20137018605A KR20130130022A KR 20130130022 A KR20130130022 A KR 20130130022A KR 1020137018605 A KR1020137018605 A KR 1020137018605A KR 20137018605 A KR20137018605 A KR 20137018605A KR 20130130022 A KR20130130022 A KR 20130130022A
Authority
KR
South Korea
Prior art keywords
phenyl
cancer
crystalline form
chloro
isopropoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020137018605A
Other languages
English (en)
Korean (ko)
Inventor
릴리 펭
바오큉 공
피오트르 에이치. 카르핀스키
릴라드하르 무를리드하르 웨이콜
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45464892&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20130130022(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20130130022A publication Critical patent/KR20130130022A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
KR1020137018605A 2010-12-17 2011-12-15 5-클로로-ｎ2-(2-이소프로폭시-5-메틸-4-피페리딘-4-일-페닐)-ｎ4[2-(프로판-2-술포닐)-페닐]-피리미딘-2,4-디아민의 결정질 형태 Withdrawn KR20130130022A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201061424194P 2010-12-17 2010-12-17
US61/424,194 2010-12-17
PCT/US2011/065030 WO2012082972A1 (en) 2010-12-17 2011-12-15 Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020187007996A Division KR20180032680A (ko) 2010-12-17 2011-12-15 5-클로로-ｎ2-(2-이소프로폭시-5-메틸-4-피페리딘-4-일-페닐)-ｎ4[2-(프로판-2-술포닐)-페닐]-피리미딘-2,4-디아민의 결정질 형태

Publications (1)

Publication Number Publication Date
KR20130130022A true KR20130130022A (ko) 2013-11-29

Family

ID=45464892

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020137018605A Withdrawn KR20130130022A (ko) 2010-12-17 2011-12-15 5-클로로-ｎ2-(2-이소프로폭시-5-메틸-4-피페리딘-4-일-페닐)-ｎ4[2-(프로판-2-술포닐)-페닐]-피리미딘-2,4-디아민의 결정질 형태
KR1020207009828A Active KR102325775B1 (ko) 2010-12-17 2011-12-15 5-클로로-ｎ2-(2-이소프로폭시-5-메틸-4-피페리딘-4-일-페닐)-ｎ4[2-(프로판-2-술포닐)-페닐]-피리미딘-2,4-디아민의 결정질 형태
KR1020197005138A Ceased KR20190022903A (ko) 2010-12-17 2011-12-15 5-클로로-ｎ2-(2-이소프로폭시-5-메틸-4-피페리딘-4-일-페닐)-ｎ4[2-(프로판-2-술포닐)-페닐]-피리미딘-2,4-디아민의 결정질 형태
KR1020187007996A Ceased KR20180032680A (ko) 2010-12-17 2011-12-15 5-클로로-ｎ2-(2-이소프로폭시-5-메틸-4-피페리딘-4-일-페닐)-ｎ4[2-(프로판-2-술포닐)-페닐]-피리미딘-2,4-디아민의 결정질 형태

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020207009828A Active KR102325775B1 (ko) 2010-12-17 2011-12-15 5-클로로-ｎ2-(2-이소프로폭시-5-메틸-4-피페리딘-4-일-페닐)-ｎ4[2-(프로판-2-술포닐)-페닐]-피리미딘-2,4-디아민의 결정질 형태
KR1020197005138A Ceased KR20190022903A (ko) 2010-12-17 2011-12-15 5-클로로-ｎ2-(2-이소프로폭시-5-메틸-4-피페리딘-4-일-페닐)-ｎ4[2-(프로판-2-술포닐)-페닐]-피리미딘-2,4-디아민의 결정질 형태
KR1020187007996A Ceased KR20180032680A (ko) 2010-12-17 2011-12-15 5-클로로-ｎ2-(2-이소프로폭시-5-메틸-4-피페리딘-4-일-페닐)-ｎ4[2-(프로판-2-술포닐)-페닐]-피리미딘-2,4-디아민의 결정질 형태

Country Status (36)

Country Link
US (2) US9309229B2 (enExample)
EP (3) EP3453708B8 (enExample)
JP (1) JP5916752B2 (enExample)
KR (4) KR20130130022A (enExample)
CN (7) CN112125884A (enExample)
AR (2) AR084309A1 (enExample)
AU (1) AU2011343775B2 (enExample)
BR (1) BR112013015000A2 (enExample)
CA (1) CA2821102C (enExample)
CL (1) CL2013001723A1 (enExample)
CO (1) CO6801792A2 (enExample)
CY (2) CY1119474T1 (enExample)
DK (2) DK2651918T3 (enExample)
EC (1) ECSP13012770A (enExample)
ES (3) ES2643016T3 (enExample)
GT (1) GT201300153A (enExample)
HR (2) HRP20171477T1 (enExample)
HU (1) HUE041845T2 (enExample)
IL (1) IL226474A (enExample)
LT (2) LT2651918T (enExample)
MA (1) MA34771B1 (enExample)
MX (1) MX338210B (enExample)
MY (2) MY177742A (enExample)
NZ (1) NZ610713A (enExample)
PE (1) PE20140698A1 (enExample)
PH (1) PH12013501254A1 (enExample)
PL (2) PL2651918T3 (enExample)
PT (2) PT2651918T (enExample)
RS (1) RS57771B1 (enExample)
RU (2) RU2746159C2 (enExample)
SG (2) SG10201510082XA (enExample)
SI (2) SI2651918T1 (enExample)
TN (1) TN2013000216A1 (enExample)
TW (2) TWI576343B (enExample)
WO (1) WO2012082972A1 (enExample)
ZA (1) ZA201303599B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2651918T (pt) 2010-12-17 2017-10-17 Novartis Ag Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propano-2-sulfonil)-fenil]-pirimidin-2,4-diamina
KR102156398B1 (ko) 2012-11-06 2020-09-15 상하이 포천 파마슈티컬 씨오 엘티디 Ａｌｋ 키나아제 억제제
KR101656382B1 (ko) * 2014-02-28 2016-09-09 한국화학연구원 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물
CN105272921A (zh) * 2014-06-09 2016-01-27 江苏奥赛康药业股份有限公司 一种制备Ceritinib的方法及其中间体化合物
CN105294649B (zh) * 2014-07-30 2019-05-14 江苏奥赛康药业股份有限公司 一种Ceritinib化合物及其药物组合物
CN105294650A (zh) * 2014-08-01 2016-02-03 江苏奥赛康药业股份有限公司 一种Ceritinib化合物及其药物组合物
LT3209647T (lt) 2014-10-21 2020-09-25 Ariad Pharmaceuticals, Inc. Kristalinės 5-chlor-n4-[-2-(dimetilfosforil)fenil]-n2-{2-metoksi-4-[4-(4-metilpiperazin-1-il) piperidin-1-il]pirimidin-2,4-diamino formos
WO2016081538A1 (en) 2014-11-18 2016-05-26 Teva Pharmaceuticals International Gmbh Solid state forms of ceritinib and salts thereof
CN105601614A (zh) * 2014-11-21 2016-05-25 奥浦顿（上海）医药科技有限公司 一种色瑞替尼晶型及其制备方法
WO2016082795A1 (zh) * 2014-11-28 2016-06-02 苏州晶云药物科技有限公司 色瑞替尼的晶型i及其制备方法
CN105622577A (zh) * 2014-11-29 2016-06-01 江苏先声药业有限公司 一种色瑞替尼的新晶型及其制备方法
WO2016108123A2 (en) * 2014-12-17 2016-07-07 Dr. Reddy’S Laboratories Limited Pure amorphous and amorphous solid dispersion of ceritinib
WO2016098070A1 (en) 2014-12-19 2016-06-23 Novartis Ag Crystalline form of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine
WO2016098042A1 (en) * 2014-12-19 2016-06-23 Novartis Ag Use of ceritinib (ldk-378) in the treatment of fes or fer mediated disorders, in particular proliferative disorders
EP3328848A1 (en) 2015-07-28 2018-06-06 Zentiva, K.S. Solid forms of ceritinib free base
CN105061397B (zh) * 2015-08-07 2018-01-02 武汉英普瑞医药科技有限公司 一种色瑞替尼的c型晶型及其制备方法与应用
CN106699743B (zh) 2015-11-05 2020-06-12 湖北生物医药产业技术研究院有限公司 嘧啶类衍生物及其用途
WO2017152858A1 (zh) * 2016-03-11 2017-09-14 苏州晶云药物科技有限公司 色瑞替尼的晶型及其制备方法
WO2017158619A1 (en) 2016-03-15 2017-09-21 Natco Pharma Limited A modified process for the preparation of ceritinib and amorphous form of ceritinib
JP2019196359A (ja) * 2019-06-17 2019-11-14 ノバルティス アーゲー ピリミジン誘導体およびそれらの中間体を調製する化学的方法
GB201915618D0 (en) 2019-10-28 2019-12-11 Univ Oslo ALK inhibitors for treatment of ALK-negative cancer and antibody-mediated diseases
CN113135905B (zh) 2020-01-17 2023-11-21 轩竹生物科技股份有限公司 多环类间变性淋巴瘤激酶抑制剂的晶型
KR20230008047A (ko) * 2020-03-30 2023-01-13 장슈 야홍 메디텍 코퍼레이션 리미티드 니트록솔린 전구약물의 결정 형태, 이를 함유하는 약학 조성물, 및 이의 제조 방법 및 이의 용도
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
JP4607879B2 (ja) * 2003-08-15 2011-01-05 ノバルティス アーゲー 新生物疾患、炎症および免疫障害の処置に有用な２，４−ピリミジンジアミン
GB0419161D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
RS53588B1 (sr) 2006-12-08 2015-02-27 Irm Llc Jedinjenja i kompozicije kao inhibitori protein kinaza
BRPI0720264B1 (pt) * 2006-12-08 2022-03-03 Novartis Ag Compostos e composições como inibidores de proteína cinase
AU2008296479A1 (en) * 2007-08-28 2009-03-12 Dana Farber Cancer Institute Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis
EP2190826A2 (en) * 2007-08-28 2010-06-02 Irm Llc 2-biphenylamino-4-aminopyrimidine derivatives as kinase inhibitors
CA2720946C (en) 2008-04-07 2013-05-28 Irm Llc Compounds and compositions as protein kinase inhibitors
PT2300013T (pt) * 2008-05-21 2017-10-31 Ariad Pharma Inc Derivados de fósforo como inibidores de cinases
CA2763717A1 (en) * 2009-06-10 2010-12-16 Cellzome Limited Pyrimidine derivatives as zap-70 inhibitors
TWI481607B (zh) 2009-12-17 2015-04-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物
US20130261154A1 (en) 2010-12-17 2013-10-03 E I Du Pont De Nemours And Company Fungicidal azocyclic amides
PT2651918T (pt) * 2010-12-17 2017-10-17 Novartis Ag Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propano-2-sulfonil)-fenil]-pirimidin-2,4-diamina
HUE038046T2 (hu) 2010-12-17 2018-09-28 Reata Pharmaceuticals Inc Antioxidáns gyulladáscsökkentõ pirazolil és pirimidinil triciklusos enonok
CN105294650A (zh) 2014-08-01 2016-02-03 江苏奥赛康药业股份有限公司 一种Ceritinib化合物及其药物组合物
WO2016081538A1 (en) 2014-11-18 2016-05-26 Teva Pharmaceuticals International Gmbh Solid state forms of ceritinib and salts thereof
US9566882B2 (en) 2014-11-21 2017-02-14 Tk Holdings Inc. Airbag module
CN105622577A (zh) 2014-11-29 2016-06-01 江苏先声药业有限公司 一种色瑞替尼的新晶型及其制备方法
BR112017011538A2 (pt) 2014-12-04 2018-03-13 Bristol-Myers Squibb Company combinação de anticorpos anti-cs1 e anti-pd1 para tratar câncer (mieloma)
WO2016098070A1 (en) 2014-12-19 2016-06-23 Novartis Ag Crystalline form of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine
EP3328848A1 (en) 2015-07-28 2018-06-06 Zentiva, K.S. Solid forms of ceritinib free base
CN105061397B (zh) 2015-08-07 2018-01-02 武汉英普瑞医药科技有限公司 一种色瑞替尼的c型晶型及其制备方法与应用

Also Published As

Publication number Publication date
AR122395A2 (es) 2022-09-07
CN104262324A (zh) 2015-01-07
MX338210B (es) 2016-04-07
EP3453708B8 (en) 2022-03-16
EP3121171B1 (en) 2018-08-15
RU2016136823A3 (enExample) 2020-02-06
MY177742A (en) 2020-09-23
KR102325775B1 (ko) 2021-11-12
RU2013132947A (ru) 2015-01-27
CY1119474T1 (el) 2018-04-04
CO6801792A2 (es) 2013-11-29
GT201300153A (es) 2014-06-09
US20130274279A1 (en) 2013-10-17
CN106831716A (zh) 2017-06-13
SG190856A1 (en) 2013-07-31
RU2599785C2 (ru) 2016-10-20
KR20180032680A (ko) 2018-03-30
RU2599785C3 (ru) 2019-04-24
PH12013501254A1 (en) 2016-07-29
SI3121171T1 (sl) 2018-11-30
TW201307299A (zh) 2013-02-16
ECSP13012770A (es) 2013-10-31
CN107056751A (zh) 2017-08-18
NZ610713A (en) 2014-10-31
CL2013001723A1 (es) 2013-12-27
US20160175305A1 (en) 2016-06-23
KR20190022903A (ko) 2019-03-06
ES2905973T3 (es) 2022-04-12
ZA201303599B (en) 2014-02-26
IL226474A (en) 2016-03-31
EP3453708A1 (en) 2019-03-13
DK2651918T3 (en) 2017-10-23
CY1121017T1 (el) 2019-12-11
CA2821102C (en) 2019-06-11
PT2651918T (pt) 2017-10-17
PE20140698A1 (es) 2014-06-11
TWI576344B (zh) 2017-04-01
DK3121171T3 (en) 2018-12-10
PL2651918T3 (pl) 2017-12-29
AU2011343775B2 (en) 2015-12-03
AR084309A1 (es) 2013-05-08
EP2651918B1 (en) 2017-07-12
AU2011343775A1 (en) 2013-07-18
CN106008462A (zh) 2016-10-12
ES2696526T3 (es) 2019-01-16
JP5916752B2 (ja) 2016-05-11
ES2643016T3 (es) 2017-11-21
US9309229B2 (en) 2016-04-12
EP2651918A1 (en) 2013-10-23
TW201629021A (zh) 2016-08-16
EP3121171A1 (en) 2017-01-25
HRP20171477T1 (hr) 2017-11-17
MY164810A (en) 2018-01-30
CN103282359A (zh) 2013-09-04
LT2651918T (lt) 2017-10-10
SI2651918T1 (sl) 2017-10-30
RU2746159C2 (ru) 2021-04-08
MX2013006952A (es) 2013-07-15
JP2013545812A (ja) 2013-12-26
CA2821102A1 (en) 2012-06-21
TWI576343B (zh) 2017-04-01
EP3453708B1 (en) 2021-10-27
WO2012082972A1 (en) 2012-06-21
TN2013000216A1 (en) 2014-11-10
PL3121171T3 (pl) 2019-01-31
KR20200039021A (ko) 2020-04-14
SG10201510082XA (en) 2016-01-28
MA34771B1 (fr) 2013-12-03
CN112125884A (zh) 2020-12-25
HUE041845T2 (hu) 2019-05-28
HRP20181737T1 (hr) 2018-12-28
CN114989139A (zh) 2022-09-02
RU2016136823A (ru) 2018-12-11
RS57771B1 (sr) 2018-12-31
BR112013015000A2 (pt) 2016-08-09
PT3121171T (pt) 2018-11-27
LT3121171T (lt) 2018-11-12
IL226474A0 (en) 2013-07-31

Similar Documents

Publication Publication Date Title
KR102325775B1 (ko) 5-클로로-ｎ2-(2-이소프로폭시-5-메틸-4-피페리딘-4-일-페닐)-ｎ4[2-(프로판-2-술포닐)-페닐]-피리미딘-2,4-디아민의 결정질 형태
US9067896B2 (en) Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl) -phenylamino]-pyrimidin-4-yl}-1-methyl-urea and salts thereof
HK40003121A (en) Process for the preparation of 5-chloro-n-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n-2-(isopropylsulfonyl)phenyl)-2,4-diamine di-hydrochloride
HK40003121B (en) Process for the preparation of 5-chloro-n-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n-2-(isopropylsulfonyl)phenyl)-2,4-diamine di-hydrochloride
HK1230180A1 (en) Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine
HK1186726B (en) Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine
HK1186726A (en) Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine
HK1230180B (en) Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine
HK1171016B (en) Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea and salts thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20130716

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20161214

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170921

Patent event code: PE09021S01D

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20180321

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20180327

WITB Written withdrawal of application